View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
March 10, 2021

Coronavirus company news summary – Sorrento Therapeutics and Mount Sinai’s Icahn School of Medicine collaborate on antibody combinations – Novartis-supported Molecular Therapeutics publish promising interim Phase I results for triple antiviral drug

By Allie Nawrat

10 March 2021

Molecular Partners and Novartis announced positive initial results from an ongoing Phase I study of ensovibep, the former’s first tri-specific Covid-19 antiviral treatment, among healthy individuals. Initial findings show the drug was safe and effective; a Phase II/III registrational study is being planned for the second quarter of 2021.

US pharmacy Walgreens has administered approximately five million Covid-19 vaccinations across its stores, long-term care facilities, and through dedicated clinics.  The company is supporting  vaccination efforts across 43 US states and jurisdictions as part of the Federal Retail Pharmacy Program.

Sorrento Therapeutics announced major progress in developing COVISHIELD antibody combinations through a license agreement with researchers at the Icahn School of Medicine at Mount Sinai. The agreement allows for the collection of antibodies which have the SARS-CoV-2 virus neutralising properties developed by Mount Sinai. This follows on from the success of Sorrento’s intravenous STI-2020 (COVI-AMG) and its intranasal STI-2099 (COVIDROPS).

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology